NCT04162158 is a Phase 1, PHASE2 clinical trial of allogeneic NK cells therapy in Hepatocellular Carcinoma, sponsored by Beijing 302 Hospital.

Who is sponsoring NCT04162158?

NCT04162158 is sponsored by Beijing 302 Hospital.

What drugs are being tested in NCT04162158?

Interventions in NCT04162158: allogeneic NK cells therapy.

What condition does NCT04162158 study?

NCT04162158 studies Hepatocellular Carcinoma.

Is NCT04162158 still recruiting?

NCT04162158 is currently status unknown. Last updated 14 November 2019.

Last reviewed 2019-11-14 · How we verify

NCT04162158

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma

Status unknown Phase 1, PHASE2 Last updated 14 November 2019

What this trial tests

Phase 1, PHASE2 trial testing allogeneic NK cells therapy in Hepatocellular Carcinoma in 200 participants. Status unknown.

Timeline

1 March 2019

Primary endpoint
1 October 2022

1 October 2024

Quick facts

Lead sponsor	Beijing 302 Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	1 March 2019
Primary completion	1 October 2022
Estimated completion	1 October 2024
Sites	1 location across China

Drugs / interventions tested

allogeneic NK cells therapy — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Beijing 302 Hospital

Who can join

Adults 18 to 65, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open-label, paired control study to evaluate the safety and clinical efficacy of allogeneic NK cells combined with targeted drug in the treatment for advanced HCC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.
Ruf B, Heinrich B, Greten TF. · · 2021 · cited 247× · PMID 33235387 · DOI 10.1038/s41423-020-00572-w
NK cells and solid tumors: therapeutic potential and persisting obstacles.
Tong L, Jiménez-Cortegana C, Tay AHM, Wickström S, et al · · 2022 · cited 134× · PMID 36319998 · DOI 10.1186/s12943-022-01672-z
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, et al · · 2022 · cited 125× · PMID 36348457 · DOI 10.1186/s13045-022-01382-5
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z, Liu X, Liang J, Liu Y, et al · · 2021 · cited 109× · PMID 34675942 · DOI 10.3389/fimmu.2021.765101
Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers.
Lei MML, Lee TKW. · · 2021 · cited 84× · PMID 34235155 · DOI 10.3389/fcell.2021.692940
Liver Cancer Immunity.
Ilyas SI, Wang J, El-Khoueiry AB. · · 2021 · cited 81× · PMID 32516437 · DOI 10.1002/hep.31416
The role of natural killer cell in gastrointestinal cancer: killer or helper.
Wang F, Lau JKC, Yu J. · · 2021 · cited 66× · PMID 33262461 · DOI 10.1038/s41388-020-01561-z
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Dai X, Guo Y, Hu Y, Bao X, et al · · 2021 · cited 58× · PMID 33537099 · DOI 10.7150/thno.54648

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Beijing 302 Hospital trials

Trials by the same sponsor.

NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04162158 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
Last refreshed: 14 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04162158.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing